Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Pranlukast is an orally bioavailable cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50s... more
Product information "Pranlukast"
Pranlukast is an orally bioavailable cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50s = 4.3-7.2 nM in radioligand binding assays). It is selective for the CysLT1 receptor over the CysLT2 receptor (IC50 = 3,620 nM for the human receptor). Pranlukast inhibits mucus secretion induced by leukotriene D4 (LTD4, Cay-20310) in isolated guinea pig trachea with an IC50 value of 0.3 µM. It inhibits TNF-alpha-induced NF-?B p65 nuclear localization in U937 and Jurkat cells when used at concentrations of 10 and 100 µM. Pranlukast inhibits bronchoconstriction induced by LTC4 (Cay-20210), LTD4, and LTE4 (Cay-20410), but not LTB4 (Cay-20110), in guinea pigs (ID50s = 0.8, 1, 0.7, and >500 µg/kg, respectively). It reduces cortical infarct volume by 81.6% and decreases neuronal death in the cortex, hippocampus, and striatum in a rat model of ischemia induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 0.03 mg/kg.Formal Name: N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide. CAS Number: 103177-37-3. Synonyms: ONO-RS-411, ONO-1078. Molecular Formula: C27H23N5O4. Formula Weight: 481.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMF:PBS (pH 7.2) (1:8): 5 mg/ml, DMSO: 10 mg/ml. lambdamax: 255, 315 nm. SMILES: O=C(Nc1cccc2c(=O)cc(oc12)c1[nH]nnn1)c1ccc(OCCCCc2ccccc2)cc1. InChi Code: InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32). InChi Key: NBQKINXMPLXUET-UHFFFAOYSA-N.
Keywords: | ONO-1078, ONO-RS-411, N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide |
Supplier: | Cayman Chemical |
Supplier-Nr: | 10008319 |
Properties
Application: | CysLT1 receptor antagonist |
MW: | 481.5 D |
Formula: | C27H23N5O4 |
Purity: | >98% |
Format: | Crystalline Solid |
Database Information
CAS : | 103177-37-3| Matching products |
KEGG ID : | K04322 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | +20°C (International: -20°C) |
Signal Word: | Warning |
GHS Hazard Pictograms: |
|
H Phrases: | H315, H319 |
P Phrases: | P264, P280, P302+352, P305+351+338, P321, P332+313, P337+313, P362+364 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed